Characterization of Doxorubicin Unknown Impurity using 1D-NMR (1H)

Doxorubicin, an anthracyline medication, is regularly used to treat a number of malignancies, including sarcoma, lung, breast, gastric, thyroid, non-Hodgkin's lymphoma, ovarian, Hodgkin's lymphoma, multiple myeloma, and childhood cancers. One unidentified doxorubicin impurity with an RRT of 1.23 and a concentration higher than 0.1% was discovered during the quality inspection of doxorubicin in bulk forms. By thoroughly analysing the 1D-NMR (1H) spectroscopic data and the LCMS mass ionization spectrum data, the structure and molecular mass of the unknown doxorubicin impurity with an RRT of 1.23 were determined. From spectroscopic data and the LC-MS mass ionization spectrum data, it was also observed that doxorubicin and unknown doxorubicin impurity with an RRT of 1.23 are interconvertible.